louisakewell, Author at European Medical Journal - Page 51 of 153

Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica

United Kingdom, November 29, 2016 – Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo gene therapies…

Janssen Submits Application to EMA Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab for the Treatment of Moderate to Severe Plaque Psoriasis

Janssen announced today the submission of a Marketing Authorisation Application to the EMA seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis.

Experts Fear Kanye West’s Breakdown is a Symptom of An Unchecked Mental Illness

According to news early this week, American rapper, songwriter, record producer, fashion designer, entrepreneur and notorious workaholic, Kanye West has…

Introducing EMJ Oncology 4.1

United Kingdom, November 15, 2016: Welcome to this year’s edition of EMJ Oncology, a must-read for all those with a passion for oncology.

State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers

This symposium provided an overview of the efficacy and safety of multikinase inhibitors in colorectal cancer, including treatment sequencing, followed…

Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma

Prof D’Amore opened the symposium by highlighting that management of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma…

Cabozantinib as First-Line Therapy for Patients with Metastatic Renal Cell Carcinoma with Poor or Intermediate-Risk Characteristics

The oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) sunitinib is a standard first-line therapy for patients with…

Regorafenib in Metastatic Colorectal Cancer and Advanced Soft Tissue Sarcomas

Oncologists face multiple challenges when treating patients with cancer, especially if patients are elderly or if they experience adverse events (AEs).

Editor’s Pick: Muscle Dysfunction in Childhood Cancer: Biological Mechanisms and Implications for Long-Term Survivorship

Paediatric cancer treatment has advanced significantly over the last half century to a point where >80% of all childhood cancer cases survive >5 years…

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML).